What CareDx (CDNA) Said on Its Q3 Earnings Call
CareDx (CDNA) reported Q3 Specialty Oncology revenue of $12.5M, up 37% YoY. Revenue per test was $823, exceeding forecasts. The company raised full-year 2026 revenue guidance to $520M-$530M and adjusted EBITDA to $90M-$100M. AlloHeme and HistoMap Kidney pipeline programs are on track for 2027 launches.
How this was made
The 30-second read
Why it matters
Traders can update valuation models using the raised full-year revenue and EBITDA ranges, plus Q4 revenue, testing volume, and gross margin expectations. The operational details (billing platform move, Epic Aura ordering integration) provide near-to-medium term execution signals.
Market read
Company-specific guidance and operational milestones are actionable for near-term positioning in CDNA, with pipeline timing and evidence-driven pricing as key swing factors.
What to watch
Epic Aura ordering start by Jan. 1, 2027 is a key dependency; any delays could shift Specialty Oncology growth timing, and longer follow-up needs for radiation de-escalation evidence could temper enthusiasm.
Background
The piece summarizes CareDx’s Q3 earnings call, focusing on NavDx (Specialty Oncology) commercialization progress, pipeline readiness for 2027 launches, and updated 2026 guidance.
Ticker impact
CareDx raised full-year 2026 revenue guidance to $520M-$530M and adjusted EBITDA to $90M-$100M, plus detailed Q4 volume and margin expectations.
Likely upward bias as the market prices in higher 2026 revenue and EBITDA, tempered by uncertainty around NavDx adoption and evidence-driven pricing.
The article discloses fresh, company-specific guidance numbers and concrete operational milestones that can change near-term expectations and model inputs.
Market effects
Reinforces demand and commercialization momentum for noninvasive transplant diagnostics, potentially improving sentiment toward the transplant diagnostics sub-group.
Primarily US-focused given Medicare pricing discussion and Epic ordering integration timeline.
Limited direct global read-through, but clinical evidence updates can influence broader oncology and transplant monitoring sentiment.
Counterpoint
Raised guidance may already reflect known momentum, and NavDx pricing upside depends on future evidence and adoption, which could disappoint if uptake or reimbursement evidence lags.
Key entities
- companyCareDx
NASDAQ-listed transplant diagnostics company reporting Q3 results and raising 2026 guidance, with NavDx commercialization and 2027 pipeline readiness updates.
- productNavDx
Specialty Oncology test for HPV-driven cancers discussed with revenue per test, Medicare pricing, and ordering integration milestones.
- pipeline_programAlloHeme
Recurrence-monitoring test for AML/MDS cell-therapy patients, targeting first-quarter 2027 launch after CLIA readiness.
- pipeline_programHistoMap Kidney
Kidney-biopsy molecular test targeting broader 2027 availability after CLIA readiness.
